December 06, 2022
Turn Biotechnologies has unveiled data at four industry conferences suggesting that a single ERA treatment may be more effective than combination therapies used today. Biomarker analysis demonstrates ERA’s regenerative impact on fibroblast proliferation, collagen VII production, and the eTurna™ lipid-based delivery platform proves groundbreakingly effective at reaching targeted tissue. The company plans to present updated...
October 28, 2022
Turn.bio has announced that its proprietary cellular reprogramming technology was able to significantly increase the proliferative and cytotoxic potential of premanufactured CAR-T cells in vitro. Turn.bio, a developer of mRNA-based cellular reprogramming technologies, has announced preliminary results from its current trial. The announcement was made by the company's co-founder, Prof. Vittorio Sebastiano, at the New...
May 19, 2022
Vittorio Sebastiano is an Associate Professor (Research) of Obstetrics and Gynecology at Stanford University and one of the most prominent scientists in the emerging field of cellular reprogramming. He is also co-founder and Scientific Advisory Board Chairman of Turn Biotechnologies, a cellular rejuvenation company based on the research done in Sebastiano’s Stanford lab. Turn recently...
April 04, 2019
We recently attended the Undoing Aging Conference in Berlin and had the opportunity to interview Professor Vittorio Sebastiano of Turn.Bio, a company developing partial cellular reprogramming techniques to reverse cellular aging. As we age, our cells experience changes to their epigenetic markers, and this, in turn, changes gene expression, which is proposed to be a...